Risk stratification of sentinel node–positive melanoma patients defines surgical management and adjuvant therapy treatment considerations-Reference-Cited by-同舟云学术

Risk stratification of sentinel node–positive melanoma patients defines surgical management and adjuvant therapy treatment considerations

Published:2018-06 Issue: Volume:96 Page:25-33
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Verver Daniëlle^ORCID,van Klaveren David,van Akkooi Alexander C.J.,Rutkowski Piotr,Powell Barry W.E.M.,Robert Caroline,Testori Alessandro,van Leeuwen Barbara L.,van der Veldt Astrid A.M.,Keilholz Ulrich,Eggermont Alexander M.M.,Verhoef Cornelis,Grünhagen Dirk J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Targeted agents and immunotherapies: optimizing outcomes in melanoma;Luke;Nat Rev Clin Oncol,2017

2. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017;Ugurel;Eur J Cancer,2017

3. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy;Eggermont;N Engl J Med,2016

4. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma;Weber;N Engl J Med,2017

5. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma;Long;N Engl J Med,2017

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stage III Melanoma;American Journal of Surgical Pathology;2024-06-20

2. Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma;Journal for ImmunoTherapy of Cancer;2024-04

3. Evolution of Melanoma and Non-Melanoma Skin Cancer Management;Landmark Papers in Plastic Surgery;2024

4. Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck – a case series and review of literature;Frontiers in Immunology;2022-10-27

5. Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I–II Melanoma Patients at Risk of Disease Relapse;Cancers;2022-06-09